oncosec medical inc (ONCS) Key Developments
OncoSec Medical and Massachusetts General Hospital to Evaluate Efficacy of Intratumoral Delivery of DNA-Based Interleukin-12
May 18 15
OncoSec Medical Inc. announced it has entered a Sponsored Research Agreement (SRA) with Massachusetts General Hospital. Under the agreement, researchers will evaluate the immunologic mechanisms underlying the anti-tumor effects of OncoSec's clinical stage platform, ImmunoPulseTM IL-12, in a Human Papilloma Virus (HPV) tumor mouse model. HPV-associated tumors include oropharyngeal and certain genitourinary cancers (e.g., cervical cancer). OncoSec's immunotherapy platform, ImmunoPulseTM IL-12, is designed to deliver and enhance the uptake of DNA-based IL-12 directly into tumors. OncoSec is currently conducting Phase II clinical trials of ImmunoPulseTM IL-12 in metastatic melanoma and plans to initiate Phase II studies in head and neck cancer and triple negative breast cancer. Preliminary data from melanoma clinical trials show evidence that ImmunoPulseTM IL-12 can generate a local immune response as well as systemic anti-tumor effects. IL-12 is an inflammatory cytokine that regulates multiple aspects of the immune system and initiates both innate and adaptive immune responses. IL-12 is a key driver of the cascade of biological events that ultimately lead to T-cell-specific killing of cancer cells. Moreover, cytokines and chemokines induced by this pathway also increase the recruitment of inflammatory T-cells into tumors.
OncoSec Medical Incorporated will Change its Ticker to ONCS.D from ONCS
May 15 15
Effective May 18, 2015, OncoSec Medical Incorporated will change its Pink Sheets LLC stock ticker symbol to ONCS.D from ONCS.
OncoSec Medical Incorporated Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 04:30 PM
May 4 15
OncoSec Medical Incorporated Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 04:30 PM. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Speakers: Punit S. Dhillon, Co-Founder, Chief Executive Officer, President and Director.
OncoSec Medical Incorporated Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 08:40 AM
Mar 25 15
OncoSec Medical Incorporated Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 08:40 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Punit S. Dhillon, Co-Founder, Chief Executive Officer, President and Director.
OncoSec Medical Incorporated Announces Earnings Results for the Six Months Ended January 31, 2015
Mar 12 15
OncoSec Medical Incorporated announced earnings results for the six months ended January 31, 2015. For the period, the company reported net loss of $8.7 million, or $0.04 per share, compared to a net loss of $4.7 million, or $0.03 per share, for the same period last year. There were no revenues for the six months ended January 31, 2015 or January 31, 2014.